• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genetic Technologies Ltd

    2/13/23 10:20:55 AM ET
    $GENE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GENE alert in real time by email
    SC 13G 1 tm236368d1_sc13g.htm SC 13G

     

     

     

    CUSIP No: 37185R307

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Genetic Technologies Limited

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    37185R307
    (CUSIP Number)

     

    February 3, 2023

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No: 37185R307 

     

    (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    623,077,200

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    623,077,200

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    623,077,200

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 37185R307 

     

    (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc. 

     
    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     
        (a)   ¨
    (b)   ¨
    (3)

    SEC USE ONLY

     

     
    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware 

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING

    PERSON WITH

    (5)

    SOLE VOTING POWER

     

    0 

    (6)

    SHARED VOTING POWER **

     

    623,077,200

    (7)

    SOLE DISPOSITIVE POWER

     

    0 

    (8)

    SHARED DISPOSITIVE POWER **

     

    623,077,200

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    623,077,200

     
    (10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     
           ¨
    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.4% 

     
    (12)

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO 

     

     

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 37185R307 

     

    Item 1.

     

    (a)    Name of Issuer

     

    Genetic Technologies Limited (the “Company”)

     

    (b)    Address of Issuer’s Principal Executive Offices

     

    60-66 Hanover Street, Fitzroy, Victoria, 3065, Australia

     

    Item 2(a).    Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).    Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)    Title of Class of Securities

     

    Ordinary shares, no par value

     

    Item 2(e)     CUSIP Number

     

    37185R307. The CUSIP Number applies to the American Depositary Shares, each of which represents six hundred (600) Shares.

     

     

     

     

    CUSIP No: 37185R307 

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.        Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of 623,077,200 Shares (represented by 1,038,462 American Depositary Shares).

     

    The Company’s Prospectus Supplement (to Prospectus dated March 23, 2020, Registration No. 333-237152), filed on February 7, 2023, indicates there were 11,541,658,143 Shares outstanding as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 37185R307 

     

    Item 5.         Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.        Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.         Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.         Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.         Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.       Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 37185R307 

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 13, 2023

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         

    By: Heights Capital Management, Inc.

    pursuant to a Limited Power of Attorney, a copy of which is attached as Exhibit I hereto

      By: /s/ Brian Sopinsky
      Name:       Brian Sopinsky
      Title:         Secretary

     

    By: /s/ Brian Sopinsky  
    Name:       Brian Sopinsky  
    Title:         Secretary  

     

     

     

     

    CUSIP No: 37185R307 

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

     

     

    CUSIP No: 37185R307 

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

      CVI Investments, Inc.

     

      By: /s/ William Walmsley
        William Walmsley, Director

     

     

     

     

    CUSIP No: 37185R307 

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of Genetic Technologies Limited, no par value, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of February 13, 2023

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky

    pursuant to a Limited Power of Attorney

      Name:       Brian Sopinsky
        Title:         Secretary

     

    By: /s/ Brian Sopinsky  
    Name:       Brian Sopinsky  
    Title:         Secretary  

     

     

    Get the next $GENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GENE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GENE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Join Genetic Technology's Exclusive Live Investor Webinar and Q&A Session on October 2

      MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE, "Company", "GTG", or "Genetic Technologies")), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies' senior leadership who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, along with progress on its recent move to a capital light model. Genetic Technologies' EasyDNA platform has over $7m in annual recur

      9/23/24 8:30:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Leadership Updates

    Live Leadership Updates

    See more
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

      MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.  More r

      7/16/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • GTG to launch U.S. Customer Digital Media Sales Campaign

      MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be

      2/28/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    SEC Filings

    See more
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/12/24 8:00:15 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      12/2/24 8:00:04 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genetic Technologies Ltd

      6-K - GENETIC TECHNOLOGIES LTD (0001166272) (Filer)

      11/20/24 8:00:07 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GENE
    Financials

    Live finance-specific insights

    See more
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV to provide a corp

      4/12/24 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 29, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Genetic Technologies: https://www.redchip.com/assets/access/gene_accessBioVie: https://www.redchip.com/assets/access/bivi_accessIn an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a

      12/29/23 9:00:00 AM ET
      $BIVI
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genetic Technologies Ltd (Amendment)

      SC 13G/A - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/14/24 2:14:47 PM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genetic Technologies Ltd

      SC 13G - GENETIC TECHNOLOGIES LTD (0001166272) (Subject)

      2/13/23 10:20:55 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care